[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100368509":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Sheffield Teaching Hospitals NHS Foundation Trust","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CardioMEMS HF System",null,"Eligible patients will be recruited and will attend for the implantation in line with standard of care procedures. The patient's details will be uploaded to the CardioMEMS HF system, enabling remote monitoring of their heart failure device. The patient will also be given a Fitbit activity monitor and set up with an account that is accessible to patient and physician to allowing activity to be monitored. The research team will be able to continuously monitor data remotely from the CardioMEMS HF system and Fitbit platform.",[13],"Device: CardioMEMS HF System",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"DEVICE","The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Alexander Rotherman","CONTACT","0114 2509550","a.rothman@sheffield.ac.uk",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Sheffield","South Yorkshire","S5 7AU","United Kingdom","UK",{"type":34,"coordinates":35},"Point",[36,37],-1.4659,53.38297,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100368509","feasibility-of-novel-clinical-trial-infrastructure-design-and-technology-for-early-phase-studies-in-patients-with-pulmonary-hypertension-fit-ph-100368509",false,"NCT04078243","Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients With Pulmonary Hypertension (FIT-PH)","Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients With Pulmonary Hypertension.","FIT-PH","Inclusion Criteria:\n\n* Diagnosis of pulmonary hypertension (Group I,II,III and IV)\n* Age 18 years\n* Estimated glomerular filtration rate (eGFR) \\> 25\n* Body mass index (BMI) \\\u003C 35 (or equivalent)\n* Pulmonary artery (PA) branch 7mm\n* Negative pregnancy test (If female of childbearing age)\n* Written, informed consent completed\n* Willingness of the patient to comply\n\nExclusion Criteria:\n\n* Group IV PH\n* Active infection\n* Pulmonary embolus (PE) or deep vein thrombosis (DVT)\n* Major cardiovascular event within past 2 months\n* Cardiac resynchronisation therapy (CRT) device within past 3 months\n* Mechanical right heart valve\n* Known coagulation disorder\n* Known hypersensitivity to aspirin or clopidogrel.","ALL","18 Years",{"count":54,"type":55},120,"ESTIMATED","OBSERVATIONAL","Prospective, open-label, observational study to evaluate the safety and feasibility of using pulmonary artery pressure (PAP) monitors and wearable activity monitors in patients with pulmonary hypertension (PH).",[59],"Pulmonary Hypertension","2025-05-29",{"date":62,"type":63},"2025-06-04","ACTUAL",{"date":65,"type":63},"2020-01-21",{"date":67,"type":55},"2028-09-06",{"name":5,"class":6},1]